Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Journal for Immunotherapy of Cancer|July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analysesAlexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.
BMC Gastroenterology|June 24, 2018
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapyR Taylor Ripley, Deborah R Surman, Laurence P Diggs, et al.
The Lancet. Oncology|January 17, 2015
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trialAnish Thomas, Arun Rajan, Arlene Berman, et al.
The Oncologist|June 6, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaSarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignanciesShivaani Kummar, Martin Gutierrez, Erin R Gardner, et al.
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.
Japanese Journal of Clinical Oncology|November 18, 2022
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trialHiroji Iwata, Rikiya Nakamura, Norikazu Masuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Nature Communications|March 30, 2024
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trialElena Giudice, Tzu-Ting Huang, Jayakumar R Nair, et al.
Pageof 14